Literature DB >> 7245119

Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.

B Nunn.   

Abstract

Collegan-induced platelet aggregation in mouse citrated platelet-rich (PRP) was associated with 5-hydroxytryptamine (5-HT) release and degranulation. Adenosine 5'-diphosphate (ADP) induced monophasic and reversible aggregation with no degranulation. Mouse platelets gave no response to adrenaline but changed shape and sometimes aggregated in response to 5-HT. Both amines potentiated the effect of ADP. The respective potencies of prostaglandin E1, papaverine, VK 774, BL 3459 and adenosine as inhibitors of ADP-induced aggregation were similar in mous and human PRP. Although ticlopidine had similar activity in the two species, aspirin and flurbiprofen were considerably less potent in mouse than human PRP as inhibitors of collagen-induced aggregation. It is suggested that collagen-induced aggregation of mouse platelets in vitro occurs by a mechanism largely independent of arachidonic acid metabolites.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7245119

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.

Authors:  Wai Ho Tang; Jeremiah Stitham; Scott Gleim; Concetta Di Febbo; Ettore Porreca; Cristiano Fava; Stefania Tacconelli; Marta Capone; Virgilio Evangelista; Giacomo Levantesi; Li Wen; Kathleen Martin; Pietro Minuz; Jeffrey Rade; Paola Patrignani; John Hwa
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

2.  Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.

Authors:  D W Thomas; R B Mannon; P J Mannon; A Latour; J A Oliver; M Hoffman; O Smithies; B H Koller; T M Coffman
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

3.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

4.  NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities.

Authors:  Heng-Lan Kuo; Jin-Cherng Lien; Ching-Hu Chung; Chien-Hsin Chang; Shyh-Chyi Lo; I-Chun Tsai; Hui-Chin Peng; Sheng-Chu Kuo; Tur-Fu Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-27       Impact factor: 3.000

5.  β₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis.

Authors:  Sergio E Chiarella; Saul Soberanes; Daniela Urich; Luisa Morales-Nebreda; Recep Nigdelioglu; David Green; James B Young; Angel Gonzalez; Carmen Rosario; Alexander V Misharin; Andrew J Ghio; Richard G Wunderink; Helen K Donnelly; Kathryn A Radigan; Harris Perlman; Navdeep S Chandel; G R Scott Budinger; Gökhan M Mutlu
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

6.  Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis.

Authors:  Scott Gleim; Jeremiah Stitham; Wai Ho Tang; Hong Li; Karen Douville; Prashen Chelikani; Jeffrey J Rade; Kathleen A Martin; John Hwa
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

7.  Platelet aggregation induced by adenosine diphosphate released from cloned murine fibrosarcoma cells is positively correlated with the experimental metastatic potential of the cells.

Authors:  Y Mogi; K Kogawa; T Takayama; N Yoshizaki; K Bannai; H Muramatsu; K Koike; Y Kohgo; N Watanabe; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1991-02

8.  The norpurpureine alkaloid from Annona purpurea inhibits human platelet activation in vitro.

Authors:  Gabriela Sánchez; Omar Estrada; Giovana Acha; Alfonso Cardozo; Franshelle Peña; Marie Christine Ruiz; Fabián Michelangeli; Claudia Alvarado-Castillo
Journal:  Cell Mol Biol Lett       Date:  2018-04-18       Impact factor: 5.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.